Diabetic Macular Edema – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of DME for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s DME forecast will answer the following questions:

• Of all people with DME, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• Of all people diagnosed with DME, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of DME over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts nine DME patient populations, as follows:

• Total prevalent cases of DME.
• DME with mild nonproliferative diabetic retinopathy.
• DME with moderate nonproliferative diabetic retinopathy.
• DME with severe nonproliferative diabetic retinopathy.
• DME with proliferative diabetic retinopathy.
• Diagnosed prevalent cases of DME.
• Undiagnosed prevalent cases of DME.
• Diagnosed drug-treated cases of DME.
• Diagnosed non-drug-treated cases of DME.

Note: Coverage may vary by country.